Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

MoonLake Immunotherapeutics (MLTX)

54.97   -0.53 (-0.96%) 09-27 11:35
Open: 55.93 Pre. Close: 55.5
High: 56.8119 Low: 54.15
Volume: 88,979 Market Cap: 2,940(M)

Technical analysis

as of: 2023-09-27 11:18:33 AM
Short-term rate:       
Stoxline posted a BUY today, upgraded from lower rating. Upward movement to be expected.
Mid-term rate:       
Target: Six months: 67.19     One year: 73.22
Support: Support1: 49.19    Support2: 40.92
Resistance: Resistance1: 57.53    Resistance2: 62.68
Pivot: 55.03
Moving Average: MA(5): 53.94     MA(20): 54.68
MA(100): 45.45     MA(250): 26.6
MACD: MACD(12,26): 0     Signal(9): 0.1
Stochastic oscillator: %K(14,3): 41.4     %D(3): 33.6
RSI: RSI(14): 52.3
52-week: High: 63.4  Low: 6.93
Average Vol(K): 3-Month: 481 (K)  10-Days: 309 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ MLTX ] has closed below upper band by 42.4%. Bollinger Bands are 22% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 55.56 - 55.78 55.78 - 56.02
Low: 51.86 - 52.09 52.09 - 52.34
Close: 55.07 - 55.44 55.44 - 55.87

Company Description

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or radiographic axial spondyloarthritis. MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland.

Headline News

Tue, 26 Sep 2023
MoonLake Immunotherapeutics Receives 'Moderate Buy' Rating ... - Best Stocks

Mon, 25 Sep 2023
MoonLake Immunotherapeutics (MLTX) Stock Falls -7.16% This Week: Is It a Good Pick? - InvestorsObserver

Mon, 25 Sep 2023
MoonLake Immunotherapeutics (NASDAQ:MLTX) Given Average ... - MarketBeat

Tue, 19 Sep 2023
Cantor Fitzgerald Reiterates MoonLake Immunotherapeutics ... - Nasdaq

Mon, 18 Sep 2023
Analyst Remains Bullish on MoonLake Immunotherapeutics MLTX - Best Stocks

Mon, 18 Sep 2023
Best Stocks 2023: These 7 Are Outperforming Nvidia - Investor's Business Daily

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 53 (M)
Shares Float 20 (M)
% Held by Insiders 4.8 (%)
% Held by Institutions 66 (%)
Shares Short 6,660 (K)
Shares Short P.Month 6,700 (K)

Stock Financials

EPS -0.95
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 9.15
Profit Margin (%) 0
Operating Margin (%) 0
Return on Assets (ttm) -11.9
Return on Equity (ttm) -18.8
Qtrly Rev. Growth 0
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -1.08
Qtrly Earnings Growth 0
Operating Cash Flow -42 (M)
Levered Free Cash Flow -23 (M)

Stock Valuations

PE Ratio -58.72
PEG Ratio 0
Price to Book value 6.08
Price to Sales 0
Price to Cash Flow -70.82

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.